Last reviewed · How we verify
Gamma Variant RBD-based ARVAC-CG vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Gamma Variant RBD-based ARVAC-CG vaccine (Gamma Variant RBD-based ARVAC-CG vaccine) — Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gamma Variant RBD-based ARVAC-CG vaccine TARGET | Gamma Variant RBD-based ARVAC-CG vaccine | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gamma Variant RBD-based ARVAC-CG vaccine CI watch — RSS
- Gamma Variant RBD-based ARVAC-CG vaccine CI watch — Atom
- Gamma Variant RBD-based ARVAC-CG vaccine CI watch — JSON
- Gamma Variant RBD-based ARVAC-CG vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Gamma Variant RBD-based ARVAC-CG vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gamma-variant-rbd-based-arvac-cg-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab